Biomedical subjects

I Dolz

Publications and source records attributed to I Dolz.

3 recordsLinked to original sources

PubMed1996

A double-blind, placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy.

Thirty patients with asthma and/or monosensitized allergic rhinitis caused by grass pollen whose ages ranged from 15 to 35 years were selected. Two groups were established at random: an active group and a placebo group, and a double-blind study was done on treatment with immunotherapy for a period of 3 continuous years, with initiation doses administered according to the rush immunotherapy technique. Grass-pollen allergen extract Alutard SQ and histamine as a placebo were used. The objective parameters of efficacy evaluated were end-point cutaneous tests, conjunctival provocation, bronchial provocation, and symptom/medication scores, as well as specific immunoglobulin determinations. The statistical evaluation of the results was significant for the differences existing between the initial and final time of the active group, and there were significant differences between the two groups for all of the parameters considered. We found no relationship between clinical improvement and the range of specific immunoglobulin E values. Regarding the safety of the treatment, systemic adverse effects were manifested only in the initial phase (rush immunotherapy), and were easily controlled by treatment. We conclude that the efficacy and safety of immunotherapy with grass pollen make it possible to consider this treatment fundamental in these patients.

Adolescent↗

PubMedDate not supplied

[Pattern electroretinogram in anterior ischemic optic neuropathy].

INTRODUCTION: Anterior ischemia optic neuropathy is defined as ischemia of the disc optic papilla nerve. The aetiology is multifactorial and causes ischemia of the optic disc and apoptosis of the nerve cells of the retina. OBJECTIVE: To study the retina of patients with anterior ischemia optic neuropathy by means of the electroretinogram pattern (PERG) to assess the function of ganglion cells of the inner layers of the retina. PATIENTS AND METHODS: We studied 12 patients referred from the Ophthalmology Department with the diagnosis of anterior ischemia optic neuropathy. The electrophysiological study consisted of PERG and PEV within 20 days of the episode. The latencies and amplitudes of the different components of the responses and the ratios of the PERG amplitudes were determined. RESULTS: No significant differences were seen in the P50 component of the PERG or the latency of the N95 component. However, statistically significant values were obtained for the amplitude N95. These differences were greater when measured from a nonlinear baseline. CONCLUSIONS: The PERG is useful for early diagnosis of patients with anterior ischaemia optic neuropathy. Measurement of the N95 is more useful when a nonlinear baseline is used. This shows dysfunction of the ganglion cells of the inner retina caused by ischaemia and retrograde degeneration of axons and cell bodies of the optic nerve.

Aged↗

PubMedDate not supplied

[Multicenter drug surveillance of sublingual immunotherapy in allergic patients].

A study of pharmacovigilance has been performed in 522 patients suffering from allergic rhinitis and/or asthma. Sensitization was due to pollens and mites in ther majority of cases. The treatment consisted in biologically standardized glycerinated allergenic extracts for specific sublingual immunotherapy (SLIT) and, major allergens were also quantified, depending on the allergenic composition. The aims of the study were to assay the effect of the SLIT in a short-and-medium-term course and to know the adverse reactions most frequently appearing, as well as the unexpected side effects that are only possible to know through the study of a numerous sample of patients. We also evaluated the factors that can modify the tolerance of the treatment, such as the onset of patient's disease and its severity. All the patients had a clinical history of, at least, two years of evolution and positive skin-prick test to the allergen/s cause of their atopic disorder. Exclusion criteria were immunotherapy in the last two years, pregnancy and those situations in which the immunotherapy is contraindicated according to the EAACI requirements. In order to carry out the daily record of the SLIT as well as the possible appearance of symptoms, two diaries were given to each patient. Tolerance was evaluated by the physician at the end of the build-up phase (3 months) and when the maintenance phase finished (5 months later). Total administered doses were 44.021, the final number of patients who registered any adverse reaction in relation with SLIT was 41 (7.9%), with a number of 67 adverse reactions that means a 0.15% over the total administered doses.(ABSTRACT TRUNCATED AT 250 WORDS)

Administration, Sublingual↗